<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321395</url>
  </required_header>
  <id_info>
    <org_study_id>GABA2020</org_study_id>
    <nct_id>NCT04321395</nct_id>
  </id_info>
  <brief_title>Vigabatrin and Insulin Sensitivity</brief_title>
  <official_title>The Effect of Vigabatrin on Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity and is&#xD;
      associated with an increased risk of developing type 2 diabetes. The hallmark feature of&#xD;
      NAFLD is an increase in intrahepatic triglyceride (IHTG) content. Data from studies conducted&#xD;
      in rodent models suggest increased IHTG content can alter hepatic vagal afferent nerve (HVAN)&#xD;
      activity. In rodent models of obesity and NAFLD, HVAN activity is reduced leading to impaired&#xD;
      insulin sensitivity and glucose control. The reduction in HVAN activity is likely due to&#xD;
      increased hepatic release of GABA, an inhibitory neurotransmitter, attributable to increased&#xD;
      expression of GABA-Transaminase (GABA-T). Pharmacological inhibition of GABA-T in obese mice&#xD;
      by treatment with vigabatrin, an irreversible inhibitor of GABA-T improves glucose tolerance&#xD;
      and reduces hyperinsulinemia, hyperglycemia, and insulin resistance. It is not known if&#xD;
      vigabatrin can also improve metabolic function in people. We propose to conduct a randomized&#xD;
      clinical controlled trial to determine the effect of vigabatrin on insulin sensitivity and&#xD;
      oral glucose tolerance in adults with obesity and NAFLD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will receive either vigabatrin or placebo</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The pharmacist will know the treatments assigned to each participant.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>3 weeks after initiation of treatment</time_frame>
    <description>Measured by hyperglycemic euglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance</measure>
    <time_frame>3 weeks after initiation of treatment</time_frame>
    <description>Measured by 75 gram oral glucose tolerance test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NAFLD</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Vigabatrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.</description>
    <arm_group_label>Vigabatrin</arm_group_label>
    <other_name>sabril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Pill, 1 pill twice daily for 7 days (days 0-6), 2 pills twice daily for 7 days (days 7-13), 3 pills twice daily for 10 days (days 14-23), 2 pills twice daily for 7 days (days 24-30), 1 pill twice daily for 7 days (days 31-37) and will discontinue on day 38.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 25-60 years old&#xD;
&#xD;
          -  BMI 30.0-49.9 kg/m2&#xD;
&#xD;
          -  IHTG content ≥5.6&#xD;
&#xD;
          -  Homeostatic Model of Insulin Resistance (HOMA-IR) Score&gt;2.5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medical, surgical, or biological menopause&#xD;
&#xD;
          -  previous bariatric surgery&#xD;
&#xD;
          -  structured exercise ≥250 min per week (e.g., brisk walking)&#xD;
&#xD;
          -  unstable weight (&gt;4% change during the last 2 months before entering the study)&#xD;
&#xD;
          -  significant organ system dysfunction (e.g., diabetes, severe pulmonary, kidney or&#xD;
             cardiovascular disease)&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  polycystic ovary syndrome&#xD;
&#xD;
          -  major psychiatric illness (including suicidal ideation or previous suicide attempts)&#xD;
&#xD;
          -  conditions that render subject unable to complete all testing procedures (e.g., severe&#xD;
             ambulatory impairments, limb amputations, or metal implants that interfere with&#xD;
             imaging procedures; coagulation disorders)&#xD;
&#xD;
          -  regular use of tobacco products&#xD;
&#xD;
          -  excessive consumption of alcohol (≥3 drinks/day for men and ≥2 drinks/day for women)&#xD;
&#xD;
          -  use of medications that are known to affect the study outcome measures or increase the&#xD;
             risk of study procedures and that cannot be temporarily discontinued for this study&#xD;
&#xD;
          -  pre-existing visual field deficits; or those at high risk of irreversible vision loss,&#xD;
             including patients with retinopathy or glaucoma&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  conditions that render subject unable to complete all testing procedures (e.g.&#xD;
             aversion to needles, metal implants that prevent magnetic resonance imaging&#xD;
&#xD;
          -  persons who are unable or unwilling to follow the study protocol&#xD;
&#xD;
          -  persons who are not able to grant voluntary informed consent&#xD;
&#xD;
          -  patients at risk for severe anemia (hemoglobin &lt; 14 g/dL (men) or &lt;12.0 g/dL (women)&#xD;
             and/or hematocrit &lt;40% in men or &lt; 37% in women)&#xD;
&#xD;
          -  patients with history of lower limb edema (risk of heart failure)&#xD;
&#xD;
          -  patients with mild or more severe renal insufficiency (CrCl &lt;100 mL/min (men) or &lt;80&#xD;
             mL/min (women))&#xD;
&#xD;
          -  patients with existing peripheral neuropathy&#xD;
&#xD;
          -  women who have active menstral cycles but are not using birth control (acceptable&#xD;
             contraception includes barrier/hormonal/IUD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah S Farabi, PhD</last_name>
    <phone>3143628554</phone>
    <email>ssfarabi@wustl.edu</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

